Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zoledronate Early to Hip Fracture Patients - Safe and Effective? A Double-blinded Randomized Controlled Treatment Strategy Trial on Zoledronate in Hip Fracture Patients

NCT05025293 is registered in ClinicalTrials.gov with Lene Bergendal Solberg as lead sponsor.

NCT NCT05025293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05025293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zoledronate Early to Hip Fracture Patients - Safe and Effective? A Double-blinded Randomized Controlled Treatment Strategy Trial on Zoledronate in Hip Fracture Patients
Lead sponsor
Lene Bergendal Solberg
Phase
Phase 4
Overall status
Completed
Start date
December 15, 2021
Completion date
June 11, 2026
Enrollment
228 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hip fractures, osteoporosis